Physicochemical Properties
| Molecular Formula | C14H11F3N2O |
| Molecular Weight | 280.25 |
| Exact Mass | 280.082 |
| CAS # | 1011244-72-6 |
| PubChem CID | 13609518 |
| Appearance | White to yellow solid powder |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 327.6±42.0 °C at 760 mmHg |
| Flash Point | 151.9±27.9 °C |
| Vapour Pressure | 0.0±0.7 mmHg at 25°C |
| Index of Refraction | 1.602 |
| LogP | 2.87 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 20 |
| Complexity | 330 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)C(F)(F)F)N |
| InChi Key | YUWBBWHECQSIKL-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C14H11F3N2O/c15-14(16,17)10-3-7-12(8-4-10)19-13(20)9-1-5-11(18)6-2-9/h1-8H,18H2,(H,19,20) |
| Chemical Name | 4-amino-N-[4-(trifluoromethyl)phenyl]benzamide |
| Synonyms | 1011244-72-6; 4-Amino-N-(4-trifluoromethylphenyl)benzamide; 824-254-4; 4-AMINO-N-[4-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE; Teriflunomide impurity 3; CHEMBL261598; 4-Amino-N-[4-(trifluoromethyl)phenyl] benzamide; 4-amino-N-(4-(trifluoromethyl)phenyl)benzamide; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | COX-1 (IC50 = 30 μM) |
| ln Vitro | Compound 11q, or teriflunomide impurity 3, is an amide-bond-reversed compound with trifluoromethyl and amino substituents that exhibited strong COX-1-selective inhibitory activity[1]. |
| References |
[1]. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. J Med Chem. 2008 Apr 24;51(8):2400-11. |
| Additional Infomation | Although cyclooxygenase-1 (COX-1) inhibition is thought to be a major mechanism of gastric damage by nonsteroidal anti-inflammatory drugs (NSAIDs), some COX-1-selective inhibitors exhibit strong analgesic effects without causing gastric damage. However, it is not clear whether their analgesic effects are attributable to COX-1-inhibitory activity or other bioactivities. Here, we report that N-(5-amino-2-pyridinyl)-4-(trifluoromethyl)benzamide ( 18f, TFAP), which has a structure clearly different from those of currently available COX-1-selective inhibitors, is a potent COX-1-selective inhibitor (COX-1 IC 50 = 0.80 +/- 0.05 microM, COX-2 IC 50 = 210 +/- 10 microM). This compound causes little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at as low a dose as 10 mg/kg. Our results show that COX-1-selective inhibitors can be analgesic agents without causing gastric damage. [1] |
Solubility Data
| Solubility (In Vitro) | DMSO: 250 mg/mL (892.06 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5682 mL | 17.8412 mL | 35.6824 mL | |
| 5 mM | 0.7136 mL | 3.5682 mL | 7.1365 mL | |
| 10 mM | 0.3568 mL | 1.7841 mL | 3.5682 mL |